Patrik Nasr

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Jag tog min läkarexamen från Linköpings Universitet 2013 och är
ST-läkare inom internmedicin samt gastroenterologi och hepatologi. Jag
försvarade min avhandling "Non-Alcoholic Fatty Liver Disease: Aspects on
Diagnosis and Long-term Prognosis" 2019 och för tillfället innehar jag en
postdoc på Karolinska Institutet. Nuvarande projekt fokuserar på
epidemiologi vid NAFLD.

Artiklar

Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2024;:1-5

Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.

Jönsson C; Bergram M; Kechagias S; Nasr P; Ekstedt M
Article: LIVER INTERNATIONAL. 2024

Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patients.

Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren Å; Nasr P; Shahnavaz A; Vessby J; Westin J; Önnerhag K; Hagström H
Article: JHEP REPORTS. 2024;6(2):100915

Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.

Akbari C; Dodd M; Stål P; Nasr P; Ekstedt M; Kechagias S; Vessby J; Rorsman F; Zhang X; Wang T; Jemielita T; Fernandes G; Engel SS; Hagström H; Shang Y
Article: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2024;:S1542-3565(24)00051-X

Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.

Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
Journal article: BMC GASTROENTEROLOGY. 2023;23(1):454

A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol.

Nasr P; Forsgren M; Balkhed W; Jönsson C; Dahlström N; Simonsson C; Cai S; Cederborg A; Henriksson M; Stjernman H; Rejler M; Sjögren D; Cedersund G; Bartholomä W; Rydén I; Lundberg P; Kechagias S; Leinhard OD; Ekstedt M
Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2023;38(9):973-984

Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019.

Nasr P; von Seth E; Mayerhofer R; Ndegwa N; Ludvigsson JF; Hagström H
Article: LANCET GASTROENTEROLOGY & HEPATOLOGY. 2023;8(8):704-713

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.

Mózes FE; Lee JA; Vali Y; Alzoubi O; Staufer K; Trauner M; Paternostro R; Stauber RE; Holleboom AG; van Dijk A-M; Mak AL; Boursier J; de Saint Loup M; Shima T; Bugianesi E; Gaia S; Armandi A; Shalimar; Lupșor-Platon M; Wong VW-S; Li G; Wong GL-H; Cobbold J; Karlas T; Wiegand J; Sebastiani G; Tsochatzis E; Liguori A; Yoneda M; Nakajima A; Hagström H; Akbari C; Hirooka M; Chan W-K; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam M; Petta S; Pennisi G; Viganò M; Ridolfo S; Aithal GP; Palaniyappan N; Lee DH; Ekstedt M; Nasr P; Cassinotto C; de Lédinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Martic M; Tuthill T; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M; LITMUS investigators
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s653

Predicting severe liver outcomes in NAFLD using repeated measurements of biomarkers-a cohort study in 1,260 patients

Shang Y; Akbari C; Dodd M; Zhang X; Wang T; Jemielita T; Fernandes G; Engel S; Nasr P; Vessby J; Rorsman F; Kechagias S; Stal P; Ekstedt M; Hagstrom H
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s707

Performance of novel collagen turnover biomarkers in relation to FIB-4 to detect advanced fibrosis in NAFLD

Hegmar H; Moller T; Nasr P; Vessby J; Kechagias S; Nyhlin N; Marschall H-U; Borssen AD; Karsdal M; Leeming D; Ekstedt M; Hagstrom H
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s605

Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients

Shang Y; Akbari C; Dodd M; Nasr P; Vessby J; Rorsman F; Kechagias S; Stal P; Ekstedt M; Hagstrom H
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s650-s651

Long-term liver-related outcomes in 1,260 patients with non-cirrhotic NAFLD

Akbari C; Dodd M; Zhang X; Wang T; Jemielita T; Fernandes G; Engel S; Nasr P; Vessby J; Rorsman F; Kechagias S; Stal P; Ekstedt M; Hagstrom H; Shang Y
Journal article: JHEP REPORTS. 2023;5(3):100663

Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD.

Linge J; Nasr P; Sanyal AJ; Dahlqvist Leinhard O; Ekstedt M
Journal article: HEPATOLOGY COMMUNICATIONS. 2023;7(1):e0003

Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD.

Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Article: LIVER INTERNATIONAL. 2022;42(12):2769-2780

Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up.

Holmer M; Ekstedt M; Nasr P; Zenlander R; Wester A; Tavaglione F; Romeo S; Kechagias S; Stål P; Hagström H
Article: HEPATOLOGY. 2022;76(5):1495-1505

Risk of cardiovascular disease and loss in life expectancy in NAFLD.

Shang Y; Nasr P; Widman L; Hagström H
Journal article: HEPATOLOGY COMMUNICATIONS. 2022;6(10):2689-2701

Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.

Ericson E; Bergenholm L; Andréasson A-C; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Journal article: HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM. 2022;21(3):349-368

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.

Kechagias S; Ekstedt M; Simonsson C; Nasr P
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s82

OS112 Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019

Nasr P; Ndegwa N; von Seth E; Ludvigsson J; Hagström H
Journal article: LIVER INTERNATIONAL. 2022;42(7):1545-1556

Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study.

Balkhed W; Åberg FO; Nasr P; Ekstedt M; Kechagias S
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s30

OS026 Liver stiffness predicts incident severe liver disease in patients with chronic liver disease

Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren Å; Nasr P; Shahnavaz A; Vessby J; Westin J; Önnerhag K; Hagström H
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s423

FRI053 The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD

Holmer M; Zenlander R; Wester A; Ekstedt M; Nasr P; Kechagias S; Romeo S; Stal P; Hagström H
Article: JOURNAL OF HEPATOLOGY. 2022;76(5):1013-1020

Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2022;57(1):60-69

Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care.

Bergram M; Nasr P; Iredahl F; Kechagias S; Rådholm K; Ekstedt M
Journal article: JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY. 2021;67:126772

Low hepatic manganese concentrations in patients with hepatic steatosis - A cohort study of copper, iron and manganese in liver biopsies.

Nasr P; Ignatova S; Lundberg P; Kechagias S; Ekstedt M
Article: HEPATOLOGY COMMUNICATIONS. 2021;5(6):1021-1035

A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease.

Åberg F; Danford CJ; Thiele M; Talbäck M; Rasmussen DN; Jiang ZG; Hammar N; Nasr P; Ekstedt M; But A; Puukka P; Krag A; Sundvall J; Erlund I; Salomaa V; Stål P; Kechagias S; Hultcrantz R; Lai M; Afdhal N; Jula A; Männistö S; Lundqvist A; Perola M; Färkkilä M; Hagström H
Journal article: BMC GASTROENTEROLOGY. 2021;21(1):180

Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol.

Nasr P; Iredahl F; Dahlström N; Rådholm K; Henriksson P; Cedersund G; Dahlqvist Leinhard O; Ebbers T; Alfredsson J; Carlhäll C-J; Lundberg P; Kechagias S; Ekstedt M
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2021;56(4):437-442

Serum levels of endotrophin are associated with nonalcoholic steatohepatitis.

Hagström H; Bu D; Nasr P; Ekstedt M; Hegmar H; Kechagias S; Zhang N; An Z; Stål P; Scherer PE
Article: JHEP REPORTS. 2021;3(2):100218

Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction.

Shang Y; Nasr P; Ekstedt M; Widman L; Stål P; Hultcrantz R; Kechagias S; Hagström H
Journal article: METABOLISM-CLINICAL AND EXPERIMENTAL. 2021;115:154439

Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.

Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2020;55(7):848-859

Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography.

Forsgren MF; Nasr P; Karlsson M; Dahlström N; Norén B; Ignatova S; Sinkus R; Cedersund G; Leinhard OD; Ekstedt M; Kechagias S; Lundberg P
Article: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2020;18(7):1592-1599.e8

Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls.

Hagström H; Nasr P; Ekstedt M; Hammar U; Widman L; Stål P; Hultcrantz R; Kechagias S; Henriksson M
Journal article: LIVER INTERNATIONAL. 2020;40(5):1069-1078

The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.

Nasr P; Fredrikson M; Ekstedt M; Kechagias S
Journal article: CURRENT PHARMACEUTICAL DESIGN. 2020;26(10):1062-1078

Modifiers of Liver-Related Manifestation in the Course of NAFLD.

Nasr P; Blomdahl J; Kechagias S; Ekstedt M
Article: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2019;17(6):1148-1156.e4

Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.

Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Article: LIVER INTERNATIONAL. 2019;39(1):197-204

Cardiovascular risk factors in non-alcoholic fatty liver disease.

Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
Journal article: HEPATOLOGY COMMUNICATIONS. 2018;2(2):199-210

Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies.

Nasr P; Ignatova S; Kechagias S; Ekstedt M
Article: HEPATOLOGY COMMUNICATIONS. 2018;2(1):48-57

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
Article: JOURNAL OF HEPATOLOGY. 2017;67(6):1265-1273

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
Journal article: DIAGNOSTIC PATHOLOGY. 2017;12(1):80

Automated quantification of steatosis: agreement with stereological point counting.

Homeyer A; Nasr P; Engel C; Kechagias S; Lundberg P; Ekstedt M; Kost H; Weiss N; Palmer T; Hahn HK; Treanor D; Lundström C
Journal article: GASTROENTEROLOGY. 2017;153(1):53-55.e7

Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis.

Nasr P; Forsgren MF; Ignatova S; Dahlström N; Cedersund G; Leinhard OD; Norén B; Ekstedt M; Lundberg P; Kechagias S
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(2):159-165

Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.

Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall H-U; Hultcrantz R; Stål P
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2017;52(1):87-91

SAF score and mortality in NAFLD after up to 41 years of follow-up.

Hagström H; Nasr P; Ekstedt M; Kechagias S; Stål P; Bedossa P; Hultcrantz R
Journal article: CURRENT HEPATITIS REPORTS. 2017;16(4):391-397

Natural History of NAFLD/NASH.

Ekstedt M; Nasr P; Kechagias S
Article: LIVER INTERNATIONAL. 2016;36(11):1688-1695

Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up.

Hagström H; Nasr P; Bottai M; Ekstedt M; Kechagias S; Hultcrantz R; Stål P
Journal article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2016;51(9):1126-1132

Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.

Nasr P; Hilliges A; Thorelius L; Kechagias S; Ekstedt M
Article: HEPATOLOGY. 2015;61(5):1547-1554

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
Visa fler

Alla övriga publikationer

Letter: GUT. 2024;:gutjnl-2023-331331

Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.

Shang Y; Akbari C; Dodd M; Nasr P; Vessby J; Rorsman F; Kechagias S; Stål P; Ekstedt M; Hagström H
Conference publication: HEPATOLOGY. 2023;78:S928-S931

CLASSIFICATION ACCORDING TO SEQUENTIALLY COMBINED NON-INVASIVE TESTS CARRIES PROGNOSTIC VALUE IN PATIENTS WITH NAFLD

Mozes FE; Kaur S; Vali Y; Alzoubi O; Wong VW-S; Li G; Wong GL-HC; Staufer K; Trauner M; Paternostro R; Stauber RE; Bugianesi E; Gaia S; Armandi A; Lupsor-Platon M; Sebastiani G; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam MM; Pennisi G; Aithal GP; Palaniyappan N; Lee D; Nasr P; Cassinotto C; De Ledinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Boursier J; De Saint Loup M; Hirooka M; Shima T; Shalimar; Hagstrom H; Ekstedt M; Akbari C; Chan WK; Tsochatzis EA; Liguori A; Petta S; Vigano M; Ridolfo S; Yoneda M; Nakajima A; Holleboom AG; Van Dijk A-M; Mak AL; Cobbold JFL; Karlas T; Wiegand J; Fournier C; Martic M; Tuthill T; Yunis C; Anstee QM; Harrison S; Bossuyt P; Pavlides M
Conference publication: HEPATOLOGY. 2023;78:S1018-S1020

NASH SEVERITY ASSESSED BY THE NAFLD ACTIVITY SCORE (NAS) DOES NOT ADD PROGNOSTIC INFORMATION TO FIBROSIS STAGE IN PATIENTS WITH NAFLD

Mozes FE; Kaur S; Vali Y; Alzoubi O; Wong VW-S; Li G; Wong GL-HC; Staufer K; Trauner M; Paternostro R; Stauber RE; Bugianesi E; Gaia S; Armandi A; Lupsor-Platon M; Sebastiani G; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam MM; Pennisi G; Aithal GP; Palaniyappan N; Lee D; Nasr P; Cassinotto C; De Ledinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Boursier J; De Saint Loup M; Hirooka M; Shima T; Dr S; Hagstrom H; Ekstedt M; Akbari C; Chan WK; Tsochatzis EA; Liguori A; Petta S; Vigano M; Ridolfo S; Yoneda M; Nakajima A; Holleboom AG; Van Dijk A-M; Mak AL; Cobbold JFL; Karlas T; Wiegand J; Fournier C; Martic M; Tuthill T; Yunis C; Anstee QM; Harrison S; Bossuyt P; Pavlides M
Conference publication: HEPATOLOGY. 2023;78:S995-S998

LIVER STIFFNESS MEASUREMENT BASED COMPOSITE SCORES HAVE COMPARABLE PROGNOSTIC PERFORMANCE TO HISTOLOGICALLY ASSESSED FIBROSIS STAGE

Mozes FE; Kaur S; Vali Y; Alzoubi O; Wong VW-S; Li G; Wong GL-HC; Staufer K; Trauner M; Paternostro R; Stauber RE; Bugianesi E; Gaia S; Armandi A; Lupsor-Platon M; Sebastiani G; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam MM; Pennisi G; Aithal GP; Palaniyappan N; Lee D; Nasr P; Cassinotto C; De Ledinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Boursier J; De Saint Loup M; Hirooka M; Shima T; Dr S; Hagstrom H; Ekstedt M; Akbari C; Chan WK; Tsochatzis EA; Liguori A; Petta S; Vigano M; Ridolfo S; Yoneda M; Nakajima A; Holleboom AG; Van Dijk A-M; Mak AL; Cobbold JFL; Karlas T; Wiegand J; Fournier C; Martic M; Tuthill T; Yunis C; Anstee QM; Harrison S; Bossuyt P; Pavlides M
Conference publication: HEPATOLOGY. 2023;78:S971-S974

HISTOLOGICALLY ASSESSED FIBROSIS IS THE MAIN DETERMINANT OF PROGNOSIS IN PATIENTS IN NAFLD

Mozes FE; Kaur S; Vali Y; Alzoubi O; Wong VW-S; Li G; Wong GL-HC; Staufer K; Trauner M; Paternostro R; Stauber RE; Bugianesi E; Gaia S; Armandi A; Lupsor-Platon M; Sebastiani G; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam MM; Pennisi G; Aithal GP; Palaniyappan N; Lee D; Nasr P; Cassinotto C; De Ledinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Boursier J; De Saint Loup M; Hirooka M; Shima T; Shalimar; Hagstrom H; Ekstedt M; Akbari C; Chan WK; Tsochatzis EA; Liguori A; Petta S; Vigano M; Ridolfo S; Yoneda M; Nakajima A; Holleboom AG; Van Dijk A-M; Mak AL; Cobbold JFL; Karlas T; Wiegand J; Fournier C; Martic M; Tuthill T; Yunis C; Anstee QM; Harrison S; Bossuyt P; Pavlides M
Conference publication: HEPATOLOGY. 2023;78:S932-S935

COMPOSITE SCORES THAT INCLUDE LIVER STIFFNESS MEASUREMENT CAN PREDICT OUTCOMES IN PATIENTS WITH NAFLD

Mozes FE; Kaur S; Vali Y; Alzoubi O; Wong VW-S; Li G; Wong GL-HC; Staufer K; Trauner M; Paternostro R; Stauber RE; Bugianesi E; Gaia S; Armandi A; Lupsor-Platon M; Sebastiani G; Mahadeva S; Rajaram R; Zheng M-H; George J; Eslam MM; Pennisi G; Aithal GP; Palaniyappan N; Lee D; Nasr P; Cassinotto C; De Ledinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Boursier J; De Saint Loup M; Hirooka M; Shima T; Shalimar D; Hagstrom H; Ekstedt M; Akbari C; Chan WK; Tsochatzis EA; Liguori A; Petta S; Vigano M; Ridolfo S; Yoneda M; Nakajima A; Holleboom AG; Van Dijk A-M; Mak AL; Cobbold JFL; Karlas T; Wiegand J; Fournier C; Martic M; Tuthill T; Yunis C; Anstee QM; Harrison S; Bossuyt P; Pavlides M
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S423

The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD

Holmer M; Zenlander R; Wester A; Ekstedt M; Nasr P; Kechagias S; Romeo S; Stal P; Hagstrom H
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S30

Liver stiffness predicts incident severe liver disease in patients with chronic liver disease

Hegmar H; Wester A; Aleman S; Backman J; Degerman E; Ekvall H; Lund K; Lundgren A; Nasr P; Shahnavaz A; Vessby J; Westin J; Onnerhag K; Hagstrom H
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S82

Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019

Nasr P; Ndegwa N; von Seth E; Ludvigsson J; Hagstrom H
Conference publication: JOURNAL OF HEPATOLOGY. 2021;75:S251-S252

Life expectancy and risk of cardiovascular disease in non-alcoholic fatty liver disease: a population-based cohort study

Shang Y; Nasr P; Widman L; Hagstrom H
Review: GASTROENTEROLOGY. 2020;158(6):1611-1625.e12

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
Conference publication: JOURNAL OF HEPATOLOGY. 2018;68:S573-S574

A new score to predict presence of advanced fibrosis in NAFLD and comparison with established scoring systems

Hagstrom H; Nasr P; Ekstedt M; Hammar U; Hultcrantz R; Stal P; Kechagias S
Conference publication: HEPATOLOGY. 2018;68:993A-994A

Health Care Costs Associated with NAFLD - a Long-Term Follow up Study

Hagstrom H; Nasr P; Ekstedt M; Hammar U; Stal P; Hultcrantz RW; Kechagias S; Henriksson M
Conference publication: HEPATOLOGY. 2018;68:950A

Cardiovascular Risk Factors in Non-Alcoholic Fatty Liver Disease

Hagstrom H; Nasr P; Ekstedt M; Hammar U; Stal P; Hultcrantz RW; Kechagias S
Review: HEPATOLOGY. 2017;65(5):1557-1565

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Dulai PS; Singh S; Patel J; Soni M; Prokop LJ; Younossi Z; Sebastiani G; Ekstedt M; Hagstrom H; Nasr P; Stal P; Wong VW-S; Kechagias S; Hultcrantz R; Loomba R
Letter: HEPATOLOGY. 2016;64(1):310-311

Reply.

Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stal P; Kechagias S; Hultcrantz R
Conference publication: JOURNAL OF HEPATOLOGY. 2016;64:S135

SAF SCORE AS A MARKER FOR MORTALITY IN NAFLD AFTER UP TO 41 YEARS OF FOLLOW-UP

Hagstrom H; Ekstedt PNM; Bedossa P; Stal P; Kechagias S; Hultcrantz R
Conference publication: HEPATOLOGY. 2016;64:18A-19A

Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease

Hagstrom H; Nasr P; Ekstedt M; Kechagias S; Onnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall H-U; Stal P; Hultcrantz RW
Conference publication: HEPATOLOGY. 2016;64:552A-553A

Risk of Mortality by Fibrosis Stage in NAFLD: A Systematic Review and Meta-Analysis

Patel JR; Dulai PS; Younossi ZM; Sebastiani G; Ekstedt M; Hagstrom H; Nasr P; Stal P; Kechagias S; Hultcrantz RW; Singh S; Loomba R
Conference publication: HEPATOLOGY. 2013;58(6):1380A-1381A

Fibrosis stage, but not NAS, is predictive for disease-specific mortality in NAFLD after 33 years of follow-up

Ekstedt M; Hagstrom H; Nasr PS; Fredrikson M; Stal P; Kechagias S; Hultcrantz RW

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI